This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug
by Zacks Equity Research
Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.
AbbVie's (ABBV) Rinvoq Gets Approval for Eczema in Europe
by Zacks Equity Research
AbbVie's (ABBV) European approval for Rinvoq for atopic dermatitis marks the fourth EC-approved indication for the JAK inhibitor drug.
Pfizer (PFE) Xeljanz Gets EC Nod for Kids Psoriatic Arthritis
by Zacks Equity Research
With the approval for polyarticular JIA and juvenile PsA, Pfizer's (PFE) Xeljanz is now approved for four indications in Europe.
Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.
Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.
Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 10.96% and 2.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
by Kinjel Shah
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN or INCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.
Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA
by Zacks Equity Research
The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion
by Zacks Equity Research
Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
REGN vs. INCY: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
by Zacks Equity Research
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
REGN vs. INCY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
by Zacks Equity Research
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
Constellation (CNST) Surges on Takeover Deal With MorphoSys
by Zacks Equity Research
Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.
Incyte (INCY) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Concert (CNCE) Initiates Second Phase III Hair Loss Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential NDA filing.
Incyte (INCY) Announces Positive Results From Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.